{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:52:17Z","timestamp":1790376737091,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jcf.2017.11.016","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T05:56:31Z","timestamp":1513317391000},"page":"271-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients"],"prefix":"10.1016","volume":"17","author":[{"given":"Jan C.","family":"Thomassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias I.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Alejandre Alcazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"van Koningsbruggen-Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2017.11.016_bb0005","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jcf.2017.11.016_bb0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2017.11.016_bb0015","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"CFRD Guidelines Committee, Clinical care guidelines for cystic fibrosis\u2013related diabetes","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care Dec"},{"issue":"7","key":"10.1016\/j.jcf.2017.11.016_bb0020","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/db05-1647","article-title":"Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury","volume":"55","author":"Stalvey","year":"2006","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.jcf.2017.11.016_bb0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"10.1016\/j.jcf.2017.11.016_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1399-543X.2004.00066.x","article-title":"Early onset diabetes mellitus. Tip or iceberg?","volume":"5","author":"Polychronakos","year":"2004","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"10.1016\/j.jcf.2017.11.016_bb0035","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"Pt 1","key":"10.1016\/j.jcf.2017.11.016_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1258\/000456307779596011","article-title":"Guidelines development group. Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis","volume":"44","author":"Green","year":"2007","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.jcf.2017.11.016_bb0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2017.11.016_bb0050","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-14-0644","article-title":"Management of endocrine disease: cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues","volume":"172","author":"Barrio","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.jcf.2017.11.016_bb0055","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.2337\/db13-1464","article-title":"Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study","volume":"63","author":"Soave","year":"2014","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.jcf.2017.11.016_bb0060","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2337\/db13-0510","article-title":"Genetic modifiers of cystic fibrosis-related diabetes","volume":"62","author":"Blackman","year":"2013","journal-title":"Diabetes"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199317309736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199317309736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T02:45:42Z","timestamp":1583030742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199317309736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1569199317309736"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2017.11.016","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2017.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}